Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease, helping to slow the progression of lung fibrosis in adult patients.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Nintedanib is used to treat fibrotic lung conditions by targeting pathways that drive fibroblast activity.

- Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: limits fibrosis development and preserves respiratory capacity. - Progressive fibrosing interstitial lung disease: decelerates overall fibrotic progression across eligible disease subtypes.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Vomiting - Abdominal pain - Decreased appetite - Weight loss

Serious or Rare Side Effects: - Elevated liver enzymes (hepatotoxicity) - Bleeding events, including gastrointestinal hemorrhage - Cardiovascular complications such as myocardial infarction - Severe infections - Gastrointestinal perforation - Life‑threatening skin reactions (e.g., Stevens‑Johnson syndrome).

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known safety concerns.

- Monitor liver function: obtain baseline and periodic liver‑function tests. - Assess bleeding risk: avoid concomitant use of strong anticoagulants unless clinically necessary. - Evaluate cardiovascular status: monitor blood pressure and signs of ischemic events. - Pregnancy considerations: avoid use during pregnancy; safety data are lacking. - Store at room temperature: keep in the original container, protect from moisture and heat.

Nintedanib can interact with other medicines that affect its metabolism or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - P‑gp inhibitors (e.g., verapamil, amiodarone): may modestly raise plasma levels. - Antacids or proton‑pump inhibitors: could affect gastrointestinal absorption. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive bleeding potential.